Drugs / crefmirlimab berdoxam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05744128 | Feb 2023 → May 2024 | melanoma, renal cell carcinoma | ImaginAb, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | ImaginAb, Inc. | Results New analysis of Phase II data at AACR assesses ImaginAb’s investigational CD8 ImmunoPET technology’s ability to predict response in immunotherapy imaginab.com ↗
The analysis shows baseline and early on-treatment CD8 ImmunoPET/CT may be able to distinguish responders from non-responders in patients receiving standard of care immune checkpoint blockade (ICB) therapy. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | crefmirlimab berdoxam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05744128 ↗ |
| Modality | Diagnostic / imaging agent | “Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.” NCT05744128 ↗ |
| Route | Intravenous | “as an IV infusion or slow bolus injection” NCT05744128 ↗ |